Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year
Half the participants from placebo arm of HIV cure trial have prolonged viral load remission when given broadly neutralising antibodies
Major US cohort reveals sharp racial disparities in HIV acquisition among trans women
People with HIV fare as well as those without it after liver transplants
Home visits and flexible PrEP cut HIV incidence by 70% in rural Kenya and Uganda
Doravirine/islatravir non-inferior to Biktarvy as first-line treatment
Machine learning: shortcut or short-circuit to enhanced HIV outcomes?
Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
PrEP uptake was already low – and then came the cuts
